This disclosure is directed to a resilient interpositional arthroplasty implant for application into a joint to pad cartilage defects, cushion, and replace or restore the articular surface, which may preserve joint integrity, reduce pain and improve function. The implant may endure variable joint compressive and shear forces and cyclic loads. The implant may repair, reconstruct, and regenerate joint anatomy, and thereby improve upon joint replacement alternatives. The walls of this invention may capture, distribute and hold living cells until aggregation and hyaline cartilage regrowth occurs. The implant may be deployed into debrided joint spaces, molding and conforming to surrounding structures with sufficient stability so as to enable immediate limb use after outpatient surgery. Appendages of the implant may repair or reconstruct tendons or ligaments, and menisci by interpositional inflatable or compliant polymer arthroplasties that promote anatomic joint motion.

A dental implant unit includes a layer of synthetically created titanium dioxide. The dental implant unit has one end for connection and a lateral surface covering the implant unit except for the end for connection. The lateral surface includes a layer of synthetically created titanium dioxide while the end for connection is free from synthetically created titanium dioxide. Also, a method produces a whitened implantable dental unit. The method includes thermal oxidation of a dental implant unit that includes titanium.

The present invention provides an orthopaedic implant including a base device having a device surface and a fixation material attached to at least one portion of the device surface. The fixation material is configured to provide a minimally sufficient adhesive force to resist natural pull out caused by forces acting on the base device after implantation and bone growth. Also provided is a method of manufacturing an orthopaedic implant. A base device with a device surface is provided and a minimally sufficient adhesive force, that can resist natural pull out caused by forces acting on the base device after implantation and bone growth, is determined. A proper amount of fixation material sufficient to provide an adhesive force equal to the minimally sufficient adhesive force is determined and fixation material is applied to the device. When the proper amount of fixation material is applied to the device surface, application is stopped.

This invention provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by a specific fluid uptake capacity value of at least 75%, which specific fluid uptake capacity value is determined by establishing a spontaneous fluid uptake value divided by a total fluid uptake value. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by having a contact angle value of less than 60 degrees, when in contact with a fluid. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which said substrate is characterized by a substantial surface roughness (Ra) as measured by scanning electron microscopy or atomic force microscopy. The invention also provides for processes for selection of an optimized coral-based solid substrate for promoting cell or tissue growth or restored function and applications of the same.

The present invention relates to the contacting of one or more surfaces of an implantable medical device with one or more diketopiperazines (DKPs).

As described below, the present invention features compositions and methods for inhibiting inflammation in connection with an acellular template (e.g., an electrospun template). In one embodiment, the template is impregnated with an agent (e.g., N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide (Cl-amidine)) that inhibits a peptidylarginine deaminase (e.g., PAD4).

Disclosed herein is a biomaterial and a method of use thereof for treating a condition. A biomaterial of the disclosure can be, for example, a surgical article. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.

The present invention relates to a formulation sized for injection comprising a biodegradable polyesteramide co-polymer comprising at least a diol of bicyclic-1,4:3,6-dianhydrohexitol and analgesics for use in the treatment of arthritic disorders. More specific the invention relates to a formulation comprising injectable microparticle according to claim 1 wherein the polyesteramide co-polymer further comprises a diacid, a diol different from bicyclic-1,4:3,6-dianhydrohexitol and at least two different amino-acids. The formulation is used to treat pain or inflammation in a patient comprising administering to said patient a therapeutically effective amount of the formulation once or twice a year.

Provided is a medical implant including: an implant base having a surface made of a silicon material; a linker having one end attached onto the surface of the implant base; and a cytokine bound to another end of the linker. By inducing the secretion of anti-inflammatory cytokines, a capsular contracture, which is one of the complications that may occur after transplantation of the patient's breast implant, may occur less.

Provided herein are compositions and their methods of use to adhere (e.g., in wet and dry environments) a variety of materials together.